Scarica l'app Stockscreener
5.80
8.23%
-0.52
Dopo l'orario di chiusura:
5.60
-0.20
-3.45%
Precedente Chiudi:
$6.32
Aprire:
$6.27
Volume 24 ore:
13,601
Relative Volume:
0.08
Capitalizzazione di mercato:
$3.09M
Reddito:
-
Utile/perdita netta:
$-12.52M
Rapporto P/E:
-0.048
EPS:
-120.8826
Flusso di cassa netto:
$-4.83M
1 W Prestazione:
-17.44%
1M Prestazione:
-26.88%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$5.60
$6.48
Intervallo di 1 settimana:
$5.60
$7.50
Portata 52W:
$5.60
$16.92
Decoy Therapeutics Inc Stock (DCOY) Company Profile
Nome
Decoy Therapeutics Inc
Settore
Industria
Telefono
346-772-0346
Indirizzo
2450 HOLCOMBE BLVD, HOUSTON
Compare DCOY vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DCOY
Decoy Therapeutics Inc
|
5.80 | 3.09M | 0 | -12.52M | -4.83M | -120.88 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Decoy Therapeutics Inc Stock (DCOY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-23 | Iniziato | Ladenburg Thalmann | Buy |
| 2020-04-27 | Iniziato | Ladenburg Thalmann | Buy |
Decoy Therapeutics Inc Borsa (DCOY) Ultime notizie
Decoy Therapeutics Inc (STU:FP11) Stock Earnings Transcripts - GuruFocus
Decoy Therapeutics Inc (STU:FP11) Stock Price & 30 Year Financial Data - GuruFocus
Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - Bitget
Decoy Therapeutics regains Nasdaq minimum bid price compliance By Investing.com - Investing.com Australia
Decoy Therapeutics regains Nasdaq minimum bid price compliance - Investing.com
Decoy Therapeutics Regains Nasdaq Compliance After Reverse Split - TipRanks
Decoy Therapeutics regains compliance with Nasdaq minimum bid price requirement - MarketScreener
Decoy Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement - TradingView
Decoy Therapeutics regains Nasdaq minimum bid compliance after reverse split - TradingView
DCOY: 2025 net loss rose to $12.5M, with cash runway into late 2026 but going concern risk persists - TradingView
Decoy Therapeutics 10-K: Net loss $12.52M, EPS $(129.10) - TradingView
Decoy Therapeutics (NASDAQ: DCOY) details AI antiviral platform, merger and reverse stock splits - Stock Titan
Decoy Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Total liabilities & shareholders' equities of Decoy Therapeutics Inc. – FWB:FP11 - TradingView
Nabriva Therapeutics (NASDAQ:NBRV) and Decoy Therapeutics (NASDAQ:DCOY) Head to Head Survey - Defense World
If You Invested $1,000 in Salarius Pharmaceuticals Inc (SLRX) - Stock Titan
Decoy Therapeutics Inc.: Fundamental Analysis and Financial Ratings | | US79400X6022 - marketscreener.com
Decoy Therapeutics Inc.: Fundamental Analysis and Financial Ratings | FP11 | US79400X6022 - marketscreener.com
Decoy Therapeutics Inc.: Fundamental Analysis and Financial Ratings | DCOY | US79400X6022 - marketscreener.com
Decoy Therapeutics partners with Quantori on AI peptide platform By Investing.com - Investing.com Nigeria
Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform - Lelezard
Decoy Therapeutics Inc. Earnings and Revenue – GETTEX:FP11 - TradingView
Debt to equity ratio of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
EBIT per share of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Price to cash flow ratio of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Free cash flow per share of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Net margin % of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Revenue per share of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Operating margin % of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Net current asset value per share of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Enterprise value to EBITDA ratio of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Non-controlling/minority interest of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Price to book ratio of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Total operating expenses of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
CapEx per share of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Equity in earnings of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
EBIT of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Total debt per share of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Debt to assets ratio of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Total common shares outstanding of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Operating income of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Enterprise value of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
EBITDA margin % of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Discontinued operations of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Decoy Therapeutics Inc. Statistics – GETTEX:FP11 - TradingView
Gross profit of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Taxes of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Preferred dividends of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Diluted shares outstanding of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
After tax other income/expense of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Diluted net income available to common stockholders of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Decoy Therapeutics Inc Azioni (DCOY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):